The Problem of Antimicrobial Resistance In Pneumonia Treatment And Its Analysis
Mahmudova Mahliyo
By: Mahmudova Mahliyo
ABSTRACT
This article analyzes the global crisis arising in the treatment of pneumonia—one of the most common and dangerous diseases of the respiratory system—specifically the issue of antimicrobial resistance. The study explores the mechanisms of drug resistance development in Streptococcus pneumoniae and other leading pathogens. Factors contributing to unchecked drug consumption among the population and the formation of hospital strains are highlighted. Furthermore, measures to establish rapid diagnostics via digital healthcare technologies and expand prophylactic vaccination are substantiated to increase the efficacy of treating respiratory tract infections.
Keywords: Pneumonia, Streptococcus pneumoniae, resistance, prophylaxis, hospital strains, antibiotic.
INTRODUCTION
Today, the treatment of pneumonia—one of the most prevalent and life-threatening infectious diseases of the respiratory system—remains one of the highest priorities for the global healthcare system. Despite fundamental advances in modern pulmonology and clinical pharmacology, pneumonia (inflammation of the lungs) continues to occupy a leading position worldwide in terms of morbidity and mortality among internal disease pathologies. According to the World Health Organization (WHO), the Antimicrobial Resistance (AMR) crisis is ranked as one of the top ten serious global public health threats of the 21st century. Annually, more than 17 million people are diagnosed with pneumonia, with men being affected 30% more frequently than women. At the same time, the mortality rate for pneumonia is significantly higher compared to other diseases: standing at 8.04% for men and 9.07% for women.
Pneumonia is categorized into the following types based on its etiology:Infectious (Bacterial): Pathogens include pneumococcus, staphylococcus, and streptococcus.Viral: Caused by various viruses.Fungal: Caused by mold, yeast fungi, and others.Mixed: In this case, the lungs can be simultaneously infected by two or more pathogens. In addition, helminths and simple parasites can also trigger pneumonia.Symptoms vary depending on the causative agent, as well as the patient’s age and general condition. Symptoms include elevated body temperature, chills, weakness, fatigue, dyspnea (difficulty breathing), chest pain, a dry cough or a productive cough with sputum (sometimes mixed with blood), body temperature rising above 38°C, and nausea.
Low drug literacy among the population represents the greatest challenge. At the onset of simple acute respiratory viral infections (ARVI), influenza, or a mild cough, many individuals immediately begin taking potent antibiotics without consulting a physician. However, antibiotics have no effect on viruses; on the contrary, they eliminate normal body microflora, creating conditions for pathogenic bacteria to “acquaint” themselves with the drug and develop resistance. If a pneumonia strain proves to be drug-resistant, a 3–5day delay can be fatal for the patient, potentially leading to sepsis or pulmonary destruction. The WHO warns that without drastic measures, deaths caused by antimicrobial resistance could surpass cancer deaths by 2050. Digitizing laboratory diagnostics and introducing technologies into hospitals that identify microbial species within hours—rather than several days—using PCR or new-generation rapid tests is essential. This enables physicians to initiate targeted therapy from the very first day. Prior to confirming pneumonia, the physician examines the patient and auscultates the lungs—where moist crackles and dullness on percussion may indicate the disease. Additionally, general and biochemical blood tests are ordered; elevations in ESR and leukocytosis serve as markers of the inflammatory process. PCR is a highly accurate laboratory method that detects the specific DNA or RNA genetic code of a pathogen (bacterial or viral) in biological material collected from the patient.
In pneumonia diagnostics, sputum, broncho alveolar lavage, or nasopharyngeal swabs are collected. DNA Extraction and Amplification: In the laboratory, the microbial genome is extracted using specialized reagents. The PCR machine amplifies (replicates) this target genetic sequence millions of times.
Result Identification: If the pathogen (e.g., Streptococcus pneumoniae) is present in the biological specimen, the machine recognizes its DNA copies and emits a signal.
Advantage: PCR can accurately detect the microbe even if present in minute quantities or in a non-viable state (for instance, if the patient has already initiated antibiotic therapy).
The most commonly used rapid tests for pneumonia include:
Urinary Antigen Test: Specific proteins of Streptococcus pneumoniae and Legionella pneumophila—the primary causative agents of pneumonia—are excreted in the patient’s urine. A urine sample is collected and applied to a specialized test cassette.
Turnaround Time: Results are available via test lines within 15–20 minutes.
Advantage: Sampling is straightforward, particularly for severe patients unable to produce sputum or for pediatric patients, enabling diagnosis directly in the emergency room. Under current conditions where antibiotic resistance is growing into a global crisis, early initiation of an accurate, targeted therapy drastically reduces the risk of severe pneumonia complications, such as sepsis, lung destruction, and infectious-toxic shock. Digitizing diagnostic capabilities and equipping healthcare facilities with new-generation tests is not merely a technical upgrade, but the most effective strategy to save lives and overcome drug resistance.
CONCLUSION
The rise of drug resistance in pneumonia therapy represents a major issue that is not only clinical but also globally epidemiological. Insufficient drug culture among the population and the unsupervised use of antibiotics for viral infections have been identified as primary drivers of bacterial genetic mutations and the destruction of normal body microflora. Expanding rapid diagnostics in hospitals and strictly regulating pharmaceutical sales represent the highest-priority strategic directions for controlling and eliminating drug resistance.
Mahmudova Mahliyo was born on May 3, 2009, in Fergana Region, Uzbekistan.
She is currently a first-year student at Fergana State University. During her studies, she is striving to expand her knowledge and abilities and acquire new skills and competencies.
Mahliyo aims to become a highly qualified specialist in her field, apply the knowledge she gains in practice, and make a meaningful contribution to the development of her country.
Similar Posts by The Mt Kenya Times:
- Democrats bet on diversity: The radical reshaping of America’s 2028 primary map
- The quiet businesses carrying Kenya’s economy
- Diaspora Times Global Aug 15 – Aug 21, 2026
- Arteta signals commitment to Arsenal as new contract looms
- Ng’ethu Secondary School was my Nineveh Mission
About the Author
